This Pharmaceutical Stock is a Top Pick at B. Riley By Investing.com
B. Riley reiterated a Buy rating on Ovid Therapeutics, Inc. after meeting CEO Meg Alexander. The firm cited catalysts for OV329 and KCC2 between year-end 2026 and early 2027, including open-label PPR topline data and ketamine challenge data, and said cash extends funding into 2029. Ovid reported Q1 results in line with expectations and dosed the first OV4071 participant.
How this was made
The 30-second read
Why it matters
The piece highlights three potential appreciation drivers: OV329 open-label PPR topline in late 2026, a pediatric TSC/IS liquid formulation that could add an orphan indication, and ketamine challenge data as the first value-ascribing event for the KCC2 platform.
Market read
Traders may use the outlined catalyst calendar to frame positioning into late-2026/early-2027, but the article does not introduce a new, hard datapoint that would force repricing today.
What to watch
Cash runway is cited, but the article does not quantify burn rate, dilution risk, or probability-weighted success for OV329/KCC2, which can dominate biotech valuation into readouts.
Background
Investing.com summarizes B. Riley’s MMV Summit discussion with Ovid CEO Meg Alexander and reiterates a Buy rating.
Ticker impact
B. Riley reiterated a Buy on Ovid Therapeutics and cited expected year-end 2026 to early 2027 catalysts across OV329 and KCC2 programs.
Near-term impact likely limited unless the market treats the outlined catalysts as a fresh schedule shift; otherwise it supports existing bullish positioning.
No new trial results, filings, or guidance numbers are disclosed here; the newest concrete items are program timing expectations and a mention of first-quarter progress (dosed first participant in OV4071), which appears more like update context than a new datapoint.
Market effects
Reinforces risk-on sentiment toward small/mid-cap biotech with near-term clinical catalysts, but provides no sector-wide regulatory or macro trigger.
None indicated.
None indicated.
Counterpoint
The catalysts are largely schedule-based and valuation narratives; without new efficacy/safety datapoints, the risk is that timelines slip or readouts disappoint.
Key entities
- public_companyOvid Therapeutics, Inc.
Subject of the analyst reiteration and catalyst timeline discussion for OV329 and KCC2 programs.
- brokerageB. Riley
Reiterated Buy rating and outlined expected clinical catalysts through early 2027.
- executiveMeg Alexander
CEO discussed at B. Riley’s MMV Summit fireside chat/panel.
